231 results on '"Skolnik, Paul R."'
Search Results
2. Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection
3. A Low-Effort, Clinic-Wide Intervention Improves Attendance for HIV Primary Care
4. Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211
5. Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211
6. Incomplete Reconstitutìon of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384
7. Patient Risks, Outcomes, and Costs of Voluntary HIV Testing at Five Testing Sites Within a Medical Center
8. Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211
9. A 24-Year-Old Patient With Crohn's Disease Starting Immunosuppressive Therapy: Vaccination Issues to Consider
10. Myositis Due to Pleistophora (Microsporidia) in a Patient with AIDS
11. Enhancement of Human Immunodeficiency Virus 1 Replication in Monocytes by 1,25-Dihydroxycholecalciferol
12. Tuberculosis of the Middle Ear: Review of the Literature with an Instructive Case Report
13. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202
14. Optimal Recall Period and Response Task for Self-Reported HIV Medication Adherence
15. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV
16. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211
17. Tumor necrosis factor alpha leads to increased cell surface expression of CXCR4 in SK-N-MC cells
18. Approaching the CDC's guidelines on the HIV testing of inpatients: physician-referral versus nonreferral-based testing
19. Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 celle, and alveolar macrophages from HIV-infected subjects
20. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men
21. Clinical implications of elevated HIV-1 viral load results obtained from samples stored frozen in vacutainer plasma preparation tubes
22. Therapeutic Drug Monitoring in Patients Coinfected with Human Immunodeficiency Virus and Disseminated Mycobacterium avium Complex
23. Randomized Controlled Trial of a Personalized Cellular Phone Reminder System to Enhance Adherence to Antiretroviral Therapy
24. Incidence and Predictors of Acute Kidney Injury in an Urban Cohort of Subjects with HIV and Hepatitis C Virus Coinfection
25. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
26. A 37-year-old man with fever and diffuse lymphadenopathy
27. Interleukin 1 Induces HIV-1 Expression in Chronically Infected U1 Cells: Blockade by Interleukin 1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein Type 1
28. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211
29. Evaluation of the Centers for Disease Control and Prevention's Recommendations Regarding Routine Testing for Human Immunodeficiency Virus by an Inpatient Service: Who Are We Missing?
30. Effective HIV Case Identification Through Routine HIV Screening at Urgent Care Centers in Massachusetts
31. Comparison of Regimens as Initial Therapy for HIV
32. HIV Therapy - What Do We Know, and When Do We Know It?
33. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects
34. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy
35. Weekly Clinicopathological Exercises: Case 5-1999: A 37-Year-Old Man with Fever and Diffuse Lymphadenopathy
36. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202
37. The effect of protease inhibitors on weight and body composition in HIV-infected patients
38. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients
39. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model
40. A Meta-analysis of the Relative Efficacy and Toxicity of Pneumocystis carinii Prophylactic Regimens
41. Invasive aspergillus sinusitis in patients with human immunodeficiency virus infection: report of two cases and review
42. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication
43. Early or Deferred Zidovudine Therapy in HIV-Infected Patients without an AIDS-Defining Illness: A Meta-Analysis
44. Soluble tumor necrosis factor receptors inhibit phorbol myristate acetate and cytokine-induced HIV-1 expression chronically infected U1 cells
45. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection
46. Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection
47. Treatment of CMV Retinitis
48. Absence of Infectious HIV-1 in the Urine of Seropositive Viremic Subjects
49. Bidirectional Interactions between Human Immunodeficiency Virus Type 1 and Cytomegalovirus
50. Therapy and Prevention of Cytomegalovirus Infections
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.